Artboard 1

What is Investigator Databank?

The Investigator Databank is a global collaboration between pharmaceutical companies to share investigator information that each company has on file with one another. Investigator Databank aims to reduce administrative burden for investigators and to increase visibility of qualified investigators to research sponsors.

Are you an investigator? Ready to get started?

Helps the busy sites like us to use a centralized data bank to timely update the site information. I wish other pharmaceutical companies will also support this effort.

Investigator, USA

Current members of the Investigator Databank include:

AbbVie, Amgen, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Janssen, Lilly, Merck Sharp & Dohme LLC, Novartis, Novo Nordisk, Pfizer, Regeneron, Roche, Sanofi, Takeda and UCB.

How can the Investigator Databank benefit Investigators?

  • Decreases administrative burden for investigators.
  • Expands investigator access to clinical research opportunities.
  • Allows investigators to view, edit, and comment on their profile.

How can I get started?

Creating a profile is easy and quick, and it allows sponsors to immediately begin viewing your details. Once registered, all you need to do is “opt-in” to start sharing with the Investigator Databank and be taken to your profile where you can view, edit, and comment on information from industry member’s clinical trial management systems.

Create a Profile

There is no charge to investigators or their institutions to opt-in to the Investigator Databank and to create a profile. Industry member companies share the financial support for development and access to the Databank.

Image of cards from within the Investigator Databank

What are the benefits to industry?

Member pharma companies benefit from the following:

  • More informed protocol planning and country selection
  • Increased access to investigators for feasibility and site identification
  • More rapid recruitment through better matching of investigators to protocols
  • Faster start-up from sharing of standard documents